RecruitingNCT07142265
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Sponsor
Novartis Pharmaceuticals
Enrollment
300 participants
Start Date
Sep 30, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria6
- Adult patients of both genders
- Myocardial Infarction diagnosis
- Dyslipidemia diagnosis
- The first injection of inclisiran no later than 14 ± 5 days after the STEMI/non-STEMI
- LDL-C > 5 mmol/L (statin-naive patients) or LDL-C > 2.5 mmol/L (on the basis of statin MTD) at the time of hospitalization or no target LDL-C level (> 1.4 mmol/L or no LDL-C level decrease by 50% on statin MTD + ezetimibe)
- Signed Informed Consent Form (ICF)
Exclusion Criteria5
- Severe oncological and somatic diseases with system and organ failure*
- Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection)
- History of therapy with PCSK9 inhibitors
- Active inflammatory liver disease or the levels of AST, ALT > 3 times, or total bilirubin > 2 times higher than the upper limit of norm
- Any other MACE in the anamnesis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07142265
Related Trials
The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field
NCT044588832 locations
Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction
NCT059206294 locations
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
NCT073624465 locations
Heart Attack Research Program: Platelet Sub-Study (HARP)
NCT030225521 location
TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome
NCT075410141 location